NeuroSense Therapeutics

Business news, market intelligence, and global industry analysis.

The Latest

Equinor activates ultra-deepwater drilling with the Valaris DS-17 drillship at Raia as Brazil's natural gas supply gap draws international capital.

Equinor (EQNR) activates $9bn Raia drilling campaign in Brazil as deepwater gas race intensifies

Representative image of AI-powered contract review software in a corporate legal workflow, illustrating how Docusign’s new AI contract review assistant could help streamline agreement analysis, redlining, and contract negotiations.

Docusign (NASDAQ: DOCU) pushes deeper into legal workflow automation with AI contract review launch

Flint Development wins Spotsylvania County approval for Patriot 95 logistics facility in Thornburg, VA

Arbor Energy signs 5 GW deal with GridMarket to supply zero-emission baseload power from 2029

Representative image of scientists analyzing neurological data during amyotrophic lateral sclerosis research, reflecting the clinical investigation behind NeuroSense Therapeutics’ PrimeC therapy following the PARADIGM Phase 2b ALS trial publication in JAMA Neurology.

NeuroSense Therapeutics (NASDAQ: NRSN) advances PrimeC development after JAMA Neurology publishes PARADIGM Phase 2b ALS trial results

JAMA Neurology publishes PARADIGM trial results showing PrimeC slowed ALS decline. Discover what this means for NeuroSense Therapeutics’ Phase 3 plans.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 16, 2026